The NS1 protein is a nonstructural protein encoded by the influenza A virus. It is responsible for many alterations produced in the cellular metabolism upon infection by the virus and for modulation of virus virulence. The NS1 protein is able to perform a large variety of functions due to its ability to bind various types of RNA molecules, from both viral and nonviral origin, and to interact with several cell factors. With the aim of exploring whether the binding of NS1 protein to viral RNA (vRNA) could constitute a novel target for the search of anti-influenza drugs, a filter-binding assay measuring the specific interaction between the recombinant His-NS1 protein from influenza A virus and a radiolabeled model vRNA ( 32 P-vNSZ) was adapted to a format suitable for screening and easy automation. Flashplate ® technology (PerkinElmer, Waltham, MA), either in 96-or 384-well plates, was used. The Flashplate ® wells were precoated with the recombinant His-NS1 protein, and the binding of His-NS1 to a 35 S-vNSZ probe was measured. A pilot screening of a collection of 27,520 mixtures of synthetic chemical compounds was run for inhibitors of NS1 binding to vRNA. We found 3 compounds in which the inhibition of NS1 binding to vRNA, observed at submicromolar concentrations, was correlated with a reduction of the cytopathic effect during the infection of cell cultures with influenza virus. These results support the hypothesis that the binding of NS1 to vRNA could be a novel target for the development of anti-influenza drugs. (Journal of Biomolecular Screening 2008:581-590) 
INTRODUCTION
Y EARLY EPIDEMICS OF HUMAN INFLUENZA virus infection occur worldwide and are associated with significant morbidity and excess mortality in large parts of the population. The World Health Organization estimates that annual influenza epidemics result in 3 to 5 million severe illnesses and 250,000 to 500,000 deaths each year in the developed world. 1 Furthermore, since the 1st cases of H5N1 avian flu were reported in 1997 in southeast Asia, there has been increasing concerns that this and other strains may develop the capacity for human-to-human transmission, thus leading to a pandemic. [2] [3] Recently, sporadic cases of highly pathogenic avian viruses in humans occurred in Hong Kong, Vietnam, Thailand, and Indonesia and may be the harbinger of an incipient pandemic. 4 Although vaccination remains the defense of choice, 5 antiviral agents are a potential alternative for either prevention or treatment in situations where the vaccine is unavailable, as in the early stages of a pandemic, or ineffective. Currently, 2 classes of antivirals are available for the treatment of influenza and prophylaxis, the adamantanes or M2 inhibitors, 6 targeting the viral ion channel, and the neuraminidase inhibitors. 7 However, their clinical use is limited by side effects including renal and mild central nervous system symptoms [8] [9] [10] [11] and the emergence of resistance. [12] [13] [14] Several attractive targets for the search of novel antiinfluenza drugs have been pursued by pharmaceutical companies. The viral hemmagglutinin, as well as the unique features of influenza virus replication, have constituted the main areas of interest. Specific inhibitors of both the hemmagglutinin and the endonuclease activity of the polymerase complex have been found after screening synthetic chemicals and natural products, [15] [16] [17] [18] [19] [20] but none, however, has passed the preclinical stage.
Influenza viruses induce a series of alterations in the synthesis and metabolism of cellular macromolecules upon infection of susceptible cells in vitro. Thus, there is some decrease in cellular mRNA synthesis, probably because of the virusinduced cap-snatching activity. Moreover, the nucleocytoplasmic transport of the cellular mRNAs is inhibited, and cellular RNAs are degraded in the nucleus. 21 The cellular mRNAs located in the cytoplasm are degraded during infection, accounting, at least in part, for the arrest of cellular protein synthesis. 22 Inhibition of cellular protein synthesis has also been reported, even in the absence of substantial cytoplasmic mRNA degradation. 21 As discussed by Ortin, 23 the influenza virus NS1 protein might be at the basis of these processes. The NS1 protein accumulates in the nucleus early in the course of the infection, and in both the nucleus and the cytoplasm at later times. In addition, NS1 has been found in association with polysomes. 24 It mediates a generalized cellular mRNA retention in the nucleus, alterations in the splicing of pre-mRNAs, and enhancement of the translation of viral but not cellular mRNAs. [25] [26] [27] The NS1 protein is able to perform such a variety of functions by its versatility in binding to various types of RNAs, from both viral and nonviral origin. Moreover, it has been shown that NS1 interacts with a model vRNA probe (vNSZ) containing the conserved termini of the influenza virus RNA segment 8 (NS segment) and a short insert of the CAT gene in negative polarity and that this binding is not competed by a 1000-fold level of unspecific unlabeled RNA. 28 The need for orally bioavailable, broad-spectrum anti-influenza drugs with new modes of action led us to explore whether the interaction between the NS1 protein and viral RNA could constitute a novel target to search for anti-influenza agents and to use high-throughput screening (HTS) technologies to facilitate the rapid identification of bioactive compounds. With this aim, a filterbinding assay measuring the interaction between the recombinant His-NS1 protein from influenza virus and a radiolabeled vNSZ probe was converted to an HTS-amenable Flashplate ® (PerkinElmer) screen. The Flashplate ® assay developed was robust enough to support the screening of chemical compound libraries looking for inhibitors of the binding of NS1 to vRNA. In agreement with our hypothesis that the binding of NS1 to vRNA could be a novel target for the search of anti-influenza drugs, we found 3 compounds in which the inhibition of NS1 binding to vRNA, observed at submicromolar concentrations, was correlated with a reduction of the cytopathic effect during the infection of cell cultures with the influenza virus.
MATERIALS AND METHODS

NS1 protein
The recombinant NS1 from the influenza A virus was expressed as a His-tagged protein in Escherichia coli BL21 from the recombinant plasmid pRNS1, purified by chromatography on Ni 2+ -NTA agarose resin and stored at -70 °C. 28
Staufen protein
The purification of the His-Staufen protein, which contains the C-terminal 476 amino acids of the Staufen protein fused to a His tag and a T7-antigenic tag, was carried out by chromatography on Ni 2+ -NTA resin as described elsewhere. 29 32 P-vNSZ (240 nucleotides) RNA was synthesized using the pNSZ plasmid as a template, as described by Perales and Ortín. 30 A modification of that method was followed to prepare 35 S-vNSZ RNA. A PCR template was prepared using the pNSZ plasmid as a template and NS gene end-specific oligodeoxynucleotides (5′-AGCAAAAGCAGGGTGACA-3′ and 5′-GAAATTAACCCTCACTAAAAGTAGAAACAAGGGTGTT-3′, this latter fused to the T3 promoter). Transcription was carried out with the MAXIscript™ T3 Kit (Ambion, Austin, TX) using 6 µM 35 S-UTP (50 µCi), 500 µM ATP, GTP, and CTP, and 1 µg of PCR DNA template, in a final volume of 20 µl, for 1 h at 37°C
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. The transcription product was purified by chromatography on Sephadex G50, analyzed in a 4% acrylamide-TBE-urea gel, and stored at -20 °C.
Unlabeled vNSZ RNA was synthesized by in vitro transcription with the MAXIscript™ T3 Kit (Ambion) using 500 µM ATP, CTP, GTP, and UTP, as described above. The transcription product was purified by chromatography on Sephadex G50, analyzed in a 2% agarose gel, quantified by measuring absorbance at 260 nm, and stored at -20 °C.
P-vNSZ binding to NS1 in filter-binding assay
Increasing amounts of purified His-NS1 protein were incubated with a fixed dose of 32 P-vNSZ (about 0.027 µCi, equivalent to 50 pg) for 20 min at 4 °C, in a buffer containing 100 mM KCl, 5 mM MgCl 2 , and 50 mM Tris, pH 7.5. The mixtures were filtered through a nitrocellulose membrane in a dot-blot apparatus. The membrane was washed with the same buffer, dried, analyzed by autoradiography, and quantified in a PhosphorImager.
S-vNSZ binding to NS1 in 96-well Flashplate ®
The 96-well Basic Flashplate ® (PerkinElmer) wells were precoated with 100 µl of NS1 protein solutions in PBS for 24 to 48 h. On the day of the assay, the wells were washed with 200 µl wash buffer (100 mM KCl, 5 mM MgCl 2 , and 50 mM Tris, pH 7.5). Then, 150 µl 2% Blocker BSA (Pierce Biotechnology, Rockford, IL) was added and allowed 2 h at 40 °C. After washing with 200 µl wash buffer, 5 µl sample plus 70 µl binding buffer (100 mM KCl, 5 mM MgCl 2 , and 50 mM Tris, pH 7.5, 0.04 U/µl Ribonuclease Inhibitor HPRI, and 1 mM DTT) were added. Then, 25 µl 35 S-vNSZ (0.027 µCi, 80 pg) in binding buffer was dispensed into each well. The reactions were incubated at room temperature for 30 min and then counted in a Topcount Scintillation Counter (Packard BioScience, Meriden, CT). Nonspecific binding was assessed in the presence of 100 ng of nonradioactive vNSZ, while total binding was measured in the presence of binding buffer. All pipetting steps were performed using the Multidrop 384 (Thermo Labsystems, Helsinki, Finland) except the addition of sample plus buffer, which was performed using a Tomtec Quadra 96 (Hamden, CT).
S-vNSZ binding to NS1 in 384-well Flashplate ®
The 384-well HTS Basic Flashplate ® (NEN Life Science Products, Boston, MA) wells were precoated with 50 µl of NS1 protein solutions in PBS for 24 to 48 h. On the day of the assay, the wells were washed with 75 µl wash buffer. Then, 75 µl 2% Blocker BSA (Pierce) was added and allowed 2 h at 40 °C. After washing with 75 µl wash buffer, 2 µl sample plus 28 µl binding buffer were added. Then, 20 µl 35 S-vNSZ (0.02 µCi, 60 pg) in binding buffer was dispensed into each well. Other experimental details were as indicated for the 96-well assay.
Screening of chemical compounds
A collection of Merck (Whitehouse Station, NJ) proprietary chemicals composed of 27,520 mixtures, each one containing 10 compounds at 2 mM in DMSO, was screened in singlet either in the 96-or 384-well assay measuring the binding between 35 S-vNSZ and NS1.
For the 96-well assay, Flashplate ® wells were precoated with 500 ng NS1, incubated with 80 pg 35 S-vNSZ (0.027 µCi), and treated as described 2 sections above. Eighty mixtures of compounds, arrayed in columns 2 to 11, were tested per plate. The compound mixtures were diluted 1:50 in binding buffer, and 5 µl of that dilution was added to a final assay volume of 100 µl, getting a final 2 µM concentration of each compound. Columns 1 and 12 of the 96-well plates were used for intraplate controls. The 4 top wells in column 1 contained 100 ng unlabeled vNSZ and served as nonspecific binding controls, and the 4 remaining wells contained vehicle only and served as total binding controls. Column 12 contained an 8-point titration curve of unlabeled vNSZ, ranging from 8 pg to 1 ng, to assess the sensitivity of the assay.
For the 384-well assay, Flashplate ® wells were precoated with 100 ng NS1 and incubated with 60 pg 35 S-vNSZ (0.020 µCi) following the conditions described in the previous section. The compound library plates, each containing 80 compounds, were diluted 1:100 in binding buffer. Four compound dilution plates, each containing 80 mixtures, were indexed into a 384well plate, arrayed in columns 3 to 22, adding 5 µl to a final assay volume of 50 µl, with a final assay concentration of 2 µM for each compound. The remaining columns in the plate were used for intraplate controls. The top 8 wells of columns 1 and 24 contained 100 ng unlabeled vNSZ as nonspecific binding controls, while the bottom 8 wells were total binding controls and contained vehicle diluent or solvent. Columns 2 and 23 contained four 8-point titration curves of unlabeled vNSZ (8 pg to 1 ng) to evaluate the sensitivity of the assay.
Compound mixture hits were titrated in the 96-well assay, in duplicate in separate plates, in 6-point curves ranging from 0.03 to 9 µM. For deconvolution of the confirmed mixture hits, the 10 separate components were tested in duplicate at 2 µM. Six-point titrations (0.03-9 µM) of the active compounds were carried out for IC50 determination.
All compound pipetting steps were performed with a Tomtec Quadra 96 with an indexer device, and all the reagents were added to the assay plates with a Multidrop 384 (Thermo Labsystems). Raw data were normalized as percentage inhibition of 35 S -vNSZ binding to NS1 relative to the total binding control average of each plate.
S-vNSZ binding to the human analog of Staufen protein in 96-well Flashplate ®
The mixture hits were titrated in 6-point curves (0.03-9 µM), in duplicate in separate plates, in a 96-well Flashplate ® assay measuring the interaction between 35 S-vNSZ and the human analog of the Staufen protein. The assay conditions were identical to those previously described for the binding of 35 S-vNSZ to NS1 with the only difference that Flashplate ® wells were precoated with 125 ng Staufen protein.
Cytotoxicity assay
MDCK cells in culture were incubated into M96 plates containing DMEM supplemented with 5% FBS at 37 °C and 5% CO 2 . The incubations were carried out both in the presence or in the absence of increasing dilutions of the test compounds. After 3 days, when the cells grew to a confluent monolayer in control plates, the cells were fixed for 30 min with 10% formaldehyde and stained for 1 h with 1% crystal violet in 20% ethanol. For the determination of the number of viable cells, the stained plates were scanned, and the images were analyzed on a Mac computer (Apple, Cupertino, CA) using the public domain NIH Image program (developed at the U.S. National Institutes of Health and available on the Internet at http://rsb .info.nih.gov/nih-image/).
Cytopathic effect inhibition assay
Confluent monolayers of MDCK cells grown in M96 plates were infected with influenza virus A/Victoria/3/75 (H3N2) at an approximate multiplicity of infection (MOI) of 1 plaque forming unit (PFU) per 1000 cells. The cultures were incubated at 37 °C and 5% CO 2 in DMEM containing 2.5 µg/ml trypsin during 3 days, in the presence of different concentrations of the compounds. When the infected controls showed a total cytopathic effect (CPE), the cells were fixed for 30 min with 10% formaldehyde and stained for 1 h with 1% crystal violet in 20% ethanol. The stained plates were scanned, and the images were analyzed on a Mac computer (Apple) using the public domain NIH Image program. The results were expressed as cell viability after viral infection in arbitrary units.
Calculation of signal-to-background ratio, signal-to-noise ratio, and Z′ ′ factor
Signal-to-background ratio in the Flashplate ® binding assays was calculated as S/B = μ s /μ b , where μ s and μ b represent the means of the signal and the background, respectively. The calculation of signal-to-noise ratio was carried out according to the expression S/N = (μ s -μ b )/σ s , where μ s and μ b are as defined above, and σ s corresponds to the standard deviation of the assay signal.
Z′ factor was calculated according to the equation
, and σ s have been defined above, and σ b is the standard deviation of the background. 31 
RESULTS AND DISCUSSION
Dot-blot assay measuring the interaction between NS1 and vRNA
The interaction between the recombinant His-tagged NS1 protein from the influenza virus and a 240-nucleotide radiolabeled viral RNA ( 32 P-vNSZ) was determined by filter binding in a dotblot format. The radiolabeled probe was specifically retained by His-NS1 protein in a dose-dependent manner (Fig. 1A) , and the assay had a low background in the absence of protein or when the probe was incubated with gelatin instead of the NS1 protein (Fig.  1B) . The apparent Kd value was in the range of 10 -7 M (Fig. 1C) , and the saturation value corresponded to about 20% to 30% of the input probe. The purified His-NS1 protein was associated to endogenous bacterial RNA that could not be removed despite testing several experimental approaches. This fact could be at the basis of the lack of complete retention of the labeled probe.
96-well Flashplate ® assay measuring the interaction between NS1 and vRNA
To convert the binding assay from a dot-blot format to another that could be easily automated and amenable for HTS, the scintillation proximity Flashplate ® technology was selected. The SPA option was initially discarded for our pilot assays because the RNA probe that we had available, previously used for the dot-blot assay, was labeled with 32 P, and the high energy from the unbound radiolabeled probe in solution would stimulate beads, resulting in an unacceptable high background level. Although Flashplate ® constitutes a homogeneous assay platform in most cases, when high energy radioligands are used, an aspiration or washing step may be added to improve signal-to-background ratios in applications where a majority of counts remain unbound in solution. The results obtained in the Flashplate ® format with the 32 P-vNSZ probe were encouraging (data not shown), but both for safety purposes and to avoid the separation step required for 32 P-labeled ligands, the 32 P-vNSZ probe was substituted by a 35 S-labeled vNSZ for further assays. Admittedly SPA technology could have also been an acceptable option using a 35 S-radiolabeled probe, maybe more cost efficient than Flashplate ® , and permitting higher density formats. However, Flashplate ® usually delivers a higher dynamic range than SPA and permits aspiration, which could be helpful to avoid quenching when libraries with a high proportion of colored compounds are tested or to increase signal-tobackground ratio if necessary. Cost efficiency, library size and characteristics, equipment, and personnel availability should be considered before selecting the best option for each laboratory.
Our assay was initially developed in a 96-well Flashplate ® format in which the recombinant His-NS1 protein was coated onto the wells of the plate, and the specific binding to a 35 conditions, the plates were precoated with different amounts of the NS1 protein, and the binding reactions were performed in the presence of various 35 S-vNSZ concentrations. As expected, NS1 precoated to Flashplate ® wells specifically bound to 35 S-vNSZ in a dose-dependent manner ( Fig. 2A) . Half of the maximum response was obtained at around 105 ng NS1, a value that was in close agreement with the results obtained in the dotblot format. Moreover, 35 S-vNSZ binding to NS1 increased linearly with the concentration of the radioactive probe when the incubation was carried out at radiolabeled vNSZ concentrations ranging from 10 to 320 pg per 100 µl (Fig. 2B) . A percentage of specific binding of 89%, corresponding to a signal-to-background ratio of approximately 9, was obtained when the plates were precoated with 500 ng His-NS1 and the incubation was run in the presence of 80 pg 35 S-vNSZ (0.027 µCi), and those were the conditions selected for further assays.
To determine the optimal incubation time for the assay, a time course study was performed, and our results indicated that the interaction between the NS1 protein and 35 S-vNSZ had already reached a steady state after 30 min (Fig. 2C) . It was observed that, in our conditions, the binding was stable for at least 18 h (data not shown).
The specificity of the interaction between the 35 S-vNSZ probe and the NS1 protein precoated onto Flashplate ® wells was assessed by displacement experiments carried out in the presence of unlabeled vNSZ. As shown in Figure 2D the concentration of the radiolabeled probe, was capable of displacing the interaction of 35 S-vNSZ and NS1 by around 90%. The effect of DMSO, the solvent commonly employed both in chemical compound and natural product extract libraries, was also studied. Our results indicated that solvent concentrations up to 10%, added to the plates precoated with NS1 30 min prior to the addition of the radiolabeled probe, did not significantly modify the binding of the 35 S-vNSZ probe to NS1 (data not shown).
In most HTS programs, each sample is assayed only in singlet. Thus, HTS assays not only require small sample volume, high throughput, and robustness but also adequate sensitivity, reproducibility, and accuracy to identify hits with high confidence. In our assay conditions, the variation coefficients were 5.5% within plates and 6.4% between plates from different runs. The signal-to-noise ratio was 16, and the signal-to-background ratio was 9.38. A Z′ factor of 0.78 was obtained ( Fig.  3) , indicating that the precision and robustness of our assay were high enough to support HTS campaigns. 31
Miniaturization of the 96-well Flashplate ® assay to a 384-well format
Our Flashplate ® assay was further miniaturized for 384-well plates. The conversion to the 384-well format, besides increasing the throughput, importantly reduced the assay cost because it was possible to decrease the amount of most of the reagents employed. As previously shown for the 96-well assay, our results indicated that NS1 precoated to the 384-well Flashplate ® specifically retained 35 S-vNSZ in a dose-dependent manner (Fig. 4A) , being approximately 37 ng NS1 the amount of precoated protein required to obtain half of the maximum response. Furthermore, 35 S-vNSZ binding to NS1 increased with the concentration of the radioactive probe (Fig. 4B) . A signal-to-background ratio of Flashplate ® wells were precoated with 100 ng of NS1. The binding to different amounts of 35 S-vNSZ ranging from 20 to 120 pg (0.006-0.041 µCi) was measured as described in Materials and Methods. The mean ± SD of the specific 35 S-vNSZ bound is shown (n = 6). (C) Competition of 35 S-vNSZ binding to NS1 by unlabeled vNSZ. Flashplate ® wells were precoated with 100 ng of NS1. Competition assays were run using 60 pg 35 S-vNSZ (0.02 µCi) and unlabeled vNSZ ranging from 0.1 pg to 10 ng. The mean ± SD of the specific 35 S-vNSZ bound is shown (n = 4). approximately 9.1, with 89% specific binding, was obtained precoating the wells with 100 ng His-NS1 and developing the binding with 60 pg 35 S-vNSZ (0.02 µCi), and those were selected as the optimal screening conditions. Competition experiments showed that unlabeled vNSZ, at 10-fold the concentration of the radiolabeled probe, was capable of displacing the binding between the 35 S-vNSZ probe and NS1 protein by 90% (Fig. 4C) . However, the concentration of unrelated unlabeled RNA required to displace the binding was over 1000-fold (data not shown). Furthermore, DMSO, at concentrations up to 10%, did not significantly alter 35 S-vNSZ binding to NS1 (data not shown).
The accuracy and robustness of the 384-well assay were assessed by determining both the intraplate and interplate VC (5.2% and 6.3%, respectively), signal-to-noise and signal-tobackground ratios (15 and 9.1, respectively), as well as the Z′ factor, which resulted to be 0.76 (Fig. 5) , indicating that our screen would be well suited for HTS.
Screening of chemical compounds
The Flashplate ® assays developed were piloted by screening a Merck collection of synthetic chemical compounds composed of 27,520 mixtures, each one containing 10 different compounds, searching for inhibitors of the binding of 35 S-vNSZ to NS1 at a final assay concentration of 2 µM. A 96-well format was used for screening 20,160 compound mixtures, and the remaining 7360 were screened in the 384-well assay.
Raw data were normalized as percentage inhibition of 35 S-vNSZ binding to NS1 relative to the total binding control. Active mixtures were defined as those causing binding inhibition higher than 40%. Eighty-eight of the 27,520 mixtures tested were active, resulting in a hit rate of 0.32%.
To address RNA binding selectivity, a counterscreen was established by measuring the binding of the same 35 S-vNSZ probe used for the primary screening to the human analog of the Staufen protein, a protein that shows a very high affinity for RNAs of different origins. 25 The 88 hits found in our primary screening were titrated for confirmation in the NS1 binding assay in 96-well format and counterscreened in the Staufen assay. From them, 75 were also active in the binding assay between the analog of the Staufen protein and vRNA and were subsequently dropped.
Specific binding of small molecules remains a significant hurdle in the validation of RNA as a drug target. Small molecules known to bind to RNA, such as aminoglycosides, guanidinium groups, and intercalative moieties, do so with little or no specificity. [32] [33] [34] The methods for assessing RNA-protein interactions are very low throughput and have lagged behind those classically employed to study protein interactions, but some efforts have been made recently to use HTS technologies to assess the inhibition of RNA-protein interactions. [35] [36] [37] Our HTS strategy, including the NS1 primary assay followed by the Staufen counterscreen, allows the identification of RNA-protein interaction inhibitors and the subsequent elimination of those that are nonselective for our target NS1 protein. In addition, although the use of 35 S-labeled vNSZ considerably decreases the rate of apparent inhibitions caused by quenching compared to that expected with a lower energy radioisotope, the Staufen counterscreen also permits to get rid of the quenching false positives.
For deconvolution of the 13 hits that selectively inhibited the binding of vNSZ to NS1, the separate components of the mixtures were assayed for the identification of the active compounds and IC50 determination. Based on their potency to inhibit the binding of 35 S-vNSZ to NS1, 5 nonstructurally related chemicals blocking the interaction between vRNA and NS1 at submicromolar concentrations ( Table 1) were selected for further biological characterization. The 8 remaining hits not tested in the biological assays were also structurally unrelated to the 5 selected for additional studies. As shown in Figure 6 , the binding inhibition caused by the 5 compounds selected for biological tests was dose dependent. The slopes of the binding inhibition curves obtained for compounds A, B, D, and E (close to -1) were compatible with competitive inhibition. However, the dose-response curve for compound C showed a steeper slope (-1.8). The fact that compound C did not inhibit the binding of vNSZ to the Staufen protein would suggest that this is not an assay artifact or a promiscuous inhibitor. A higher instability of this compound could explain the steep dose-response curve observed for compound C.
Further studies would be required to determine whether the observed inhibition of the binding of vRNA to NS1 caused by these compounds is due to direct interaction of the compounds with the vNSZ probe or with the NS1 protein.
Reduction of virus replication by NS1 inhibitors
The effect of the 5 inhibitors on virus-induced cell death was determined in MDCK cell cultures infected with the influenza virus. Compounds A, B, and C reduced the capability of the influenza virus to infect MDCK cells (Fig. 7A) in the absence of apparent cytotoxicity (Fig. 7B) . In contrast, compounds D and E failed to reduce the cytopathic action of the virus (data not shown). Compound A lowered the infection capability of the influenza virus at concentrations between 2 to 4 µM, and no cytotoxic effect of this compound was observed up to 4 µM. Compound B decreased the cytopathic action of the virus at 4 µM, with no cytotoxic effect at that concentration. Compound C showed the most potent antiviral effect, diminishing the viral cytopathic action at concentrations ranging from 0.5 to 4 µM, in the absence of any cytotoxic effect at concentrations below 8 µM. In agreement with the above results, compound C reduced the yield of the influenza virus infection by more than 100-fold when present at 4 µM (data not shown). Our findings, although preliminary, substantiate the potential utility of the interaction of NS1 and vRNA as a novel target for the search of anti-influenza drugs, amenable for HTS using a homogeneous Flashplate ® platform. Using this assay, we have found 3 compounds in which the inhibition of NS1 binding to vRNA, observed in the submicromolar range, was correlated with a reduction of the cytopathic effect and virus yield during the infection of cell cultures with the influenza virus. Table 1 shows some physicochemical and biological characteristics of the 5 compounds selected for viral cytopathic tests. As shown, the 3 compounds that reduced influenza virus cytopathic action fully comply with the Lipinski "rule-of-5," 38 suggesting that they would present acceptable drug-like properties. Although the therapeutic window observed for the 3 inhibitors found in this pilot screening is narrow, it is conceivable that derivatives of these compounds could be designed with improved therapeutic index. In addition, the application of this screening assay on larger collections of chemicals is likely to result in the identification of additional hits that could be useful to define the real potential of the inhibitors of viral RNA-NS1 interaction for the development of novel antiinfluenza drugs.
